Ensuring Access to Lower-Cost Medicines for Seniors Act
- Bill Number
- S. 4323
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-04-16: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-05-18T19:29:17Z
AI-Generated Summary
Purpose
The Ensuring Access to Lower-Cost Medicines for Seniors Act (S. 4323) aims to increase Medicare Part D beneficiaries' access to lower-cost generic drugs and biosimilar biological products (biosimilars: drugs highly similar to expensive biologic drugs, often cheaper) by requiring prescription drug plans (PDPs) and Medicare Advantage prescription drug plans (MA-PD plans) to include these on their formularies (approved lists of covered drugs) and place them in favorable cost-sharing tiers.
Key Provisions
- Mandatory Formulary Inclusion (effective plan years starting January 1, 2028):
- If a formulary includes a brand-name "reference drug" or "reference biological product," it must also include:
- Each cheaper generic version (based on wholesale acquisition cost, or WAC: a published list price for drugs excluding discounts).
- At least one cheaper biosimilar for the reference biologic (if available).
- Plans cannot impose stricter access limits (e.g., prior authorization, step therapy) on these generics/biosimilars than on the reference products.
- Cost-Sharing Tier Requirements:
- Must create at least one tier only for generics and biosimilars with no cost-sharing or a copayment/coinsurance at least $20 lower than the lowest brand-drug tier.
- For plans with a "specialty tier" (for high-cost drugs), must add a second specialty tier for high-cost generics/biosimilars with coinsurance at least 5 percentage points lower than other specialty tiers.
- Required generics/biosimilars must be placed on these low-cost tiers.
- Implementation Rules:
- The Secretary of Health and Human Services (via CMS) sets uniform standards for determinations (quarterly during plan year) and prompt formulary updates.
- Rules apply after any deductible; deductibles on generics/biosimilars cannot exceed those on other drugs (with limited exceptions).
- Definitions include specifics for generics (FDA-approved under abbreviated pathway), biosimilars, reference products, and WAC.
Significant Changes to Existing Law
- Amends Section 1860D-4(b)(3) of the Social Security Act to add new subparagraphs (J) and (K) mandating formulary inclusion and tiering.
- Makes conforming changes to Section 1860D-2 to integrate these rules into benefit design, low-income subsidy protections, and fallback coverage.
Potential Impacts
- Medicare Beneficiaries (Citizens): Lower out-of-pocket costs and easier access to affordable equivalents of brand drugs, potentially reducing prescription expenses for seniors.
- Government Agencies: CMS must develop and enforce uniform requirements, monitor compliance, and approve plan designs, increasing administrative oversight.
- Health Plans: PDPs and MA-PD plans face mandates to revise formularies, tiers, and access rules, possibly raising operational costs but promoting cost savings through generics/biosimilars.
- No direct impacts on international relations.
Main Stakeholders Affected
- Medicare Part D Enrollees (primarily seniors): Gain better access and lower costs.
- PDP Sponsors and MA Organizations: Must comply with new formulary and tiering rules.
- Pharmaceutical Manufacturers: Generic and biosimilar makers benefit from required inclusion; brand-name makers may see reduced preference.
- CMS (Department of Health and Human Services): Responsible for implementation and guidance.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens Medicare Part D regulations on formularies without altering core eligibility or funding; relies on Secretary's authority for flexible implementation (e.g., cost thresholds).
- Constitutional: No apparent challenges; aligns with Congress's spending power over federal programs like Medicare.
- Political: Bipartisan sponsorship (Sens. Lankford and Hassan); promotes competition to lower drug costs, but could spark debate over plan flexibility vs. beneficiary protections.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Sen. Hassan, Margaret Wood [D-NH]
Recent Actions
- 2026-04-16: Read twice and referred to the Committee on Finance.
- 2026-04-16: Introduced in Senate
Bill Versions
- Ensuring Access to Lower-Cost Medicines for Seniors Act — issued 2026-04-16 — PDF (13 pages)